Compare BridgeBio Pharma Inc (BBIO) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? BridgeBio Pharma Inc trades at $84.71 (market cap $16.46B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.19. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | XDTE | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.17 | $44.76 |
52-Week Low | $44.81 | $36.00 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
XDTE is trading at $38.91, down 0.74% on the day, with a bearish technical signal from moving averages. The ETF focuses on generating high income through a 0DTE covered call strategy on the S&P 500, offering frequent dividend distributions. Recent news highlights its role in providing daily and weekly income, though some sources note risks associated with potential NAV erosion.
The outlook for XDTE centers on its high-yield income strategy, but investors face significant risks from market volatility and NAV decline. While the fund appeals for tax-efficient weekly payouts, its performance is highly sensitive to S&P 500 movements and options market conditions, warranting caution amid bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
